核因子红细胞 2 (NF-E2) 相关因子 3 (NFE2L3) 是 CNC-bZIP 亚家族的成员，广泛存在于多种组织中，是一种可释放的内质网 (ER) 膜锚定转录因子从内质网移入细胞核，与启动子区域结合，调节一系列参与抗氧化、炎症反应和细胞周期调节以应对细胞外或细胞内应激的靶基因。最近的研究，特别是过去 5 年的研究，揭示了 NFE2L3 参与多种生物过程，包括细胞分化、炎症反应、脂质稳态、免疫反应和肿瘤生长。值得注意的是，NFE2L3已被确定为多种癌症的发生和预后的关键参与者，包括结直肠癌、甲状腺癌、乳腺癌、肝细胞癌、胃癌、肾癌、膀胱癌、食管鳞状细胞癌、T细胞淋巴母细胞淋巴瘤、胰腺癌和鳞状细胞癌。此外，研究已将 NFE2L3 与其他癌症联系起来，如肺腺癌、恶性胸膜间皮瘤、卵巢癌、多形性胶质母细胞瘤和喉癌，表明其作为创新癌症治疗方法的靶点的潜力。因此，为了更好地了解NFE2L3在疾病中的作用，本文对NFE2L3的发现、结构、功能和研究进展进行深入探讨，为NFE2L3靶向癌症疗法的开发奠定基础。 © 2024 熊、李、姚、杨、向。

Nuclear factor erythroid 2 (NF-E2)-related factor 3 (NFE2L3), a member of the CNC-bZIP subfamily and widely found in a variety of tissues, is an endoplasmic reticulum (ER) membrane-anchored transcription factor that can be released from the ER and moved into the nucleus to bind the promoter region to regulate a series of target genes involved in antioxidant, inflammatory responses, and cell cycle regulation in response to extracellular or intracellular stress. Recent research, particularly in the past 5 years, has shed light on NFE2L3's participation in diverse biological processes, including cell differentiation, inflammatory responses, lipid homeostasis, immune responses, and tumor growth. Notably, NFE2L3 has been identified as a key player in the development and prognosis of multiple cancers including colorectal cancer, thyroid cancer, breast cancer, hepatocellular carcinoma, gastric cancer, renal cancer, bladder cancer, esophageal squamous cell carcinoma, T cell lymphoblastic lymphoma, pancreatic cancer, and squamous cell carcinoma. Furthermore, research has linked NFE2L3 to other cancers such as lung adenocarcinoma, malignant pleural mesothelioma, ovarian cancer, glioblastoma multiforme, and laryngeal carcinoma, indicating its potential as a target for innovative cancer treatment approaches. Therefore, to gain a better understanding of the role of NFE2L3 in disease, this review offers insights into the discovery, structure, function, and recent advancements in the study of NFE2L3 to lay the groundwork for the development of NFE2L3-targeted cancer therapies.Copyright © 2024 Xiong, Li, Yao, Yang and Xiang.